Basis: FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/FCF ratio is N/A as of 2026-10-06T18:28:33.265Z.
Calculation as of: 2026-10-06T18:28:33.265Z.
Quote observation: 2026-10-06T18:25:02.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7c85ff734d2850511ecc65d4372fb375f497d0f47939b952c94dba1281e34a39
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/FCF RATIO
N/A
Market Cap
$50.86M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$52.46M
Price/FCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$49.55M
Price/FCF Ratio
N/A
TTM Avg
62.26
3Y Avg
60.70
5Y Avg
63.54
| NAME | MARKET CAP | PRICE/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tenax Therapeutics, Inc. (TENX) | $51.19M | N/A | N/A | N/A | N/A |
| eXoZymes, Inc. (EXOZ)vs › | $51.42M | N/A | N/A | N/A | N/A |
| Eloxx Pharmaceuticals, Inc. (ELOX)vs › | $50.86M | N/A | N/A | N/A | N/A |
| Clene Inc. (CLNN)vs › | $50.83M | N/A | N/A | N/A | N/A |
| Envoy Medical, Inc. (COCH)vs › | $50.64M | N/A | N/A | N/A | N/A |
| biote Corp. (BTMD)vs › | $51.83M | 2.63 | 2.45 | 5.29 | 4.64 |
| Dogwood Therapeutics, Inc. (DWTX)vs › | $52.46M | N/A | N/A | N/A | N/A |
| Aldeyra The (ALDX)vs › | $52.73M | N/A | N/A | N/A | N/A |
| Sensus Healthcare, Inc. (SRTS)vs › | $49.55M | N/A | 62.26 | 60.70 | 63.54 |
| Apollomics, Inc. (APLM)vs › | $49.52M | N/A | N/A | N/A | N/A |
P/FCF Ratio
N/A
FCF Yield
N/A
P/FCF measures market price relative to free cash flow per share. Free cash flow is operating cash flow after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
